1. Home
  2. BMBL vs VSTM Comparison

BMBL vs VSTM Comparison

Compare BMBL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bumble Inc.

BMBL

Bumble Inc.

HOLD

Current Price

$3.27

Market Cap

472.2M

Sector

Technology

ML Signal

HOLD

Logo Verastem Inc.

VSTM

Verastem Inc.

HOLD

Current Price

$4.73

Market Cap

470.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMBL
VSTM
Founded
2014
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
472.2M
470.7M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
BMBL
VSTM
Price
$3.27
$4.73
Analyst Decision
Hold
Strong Buy
Analyst Count
13
7
Target Price
$4.46
$16.50
AVG Volume (30 Days)
3.3M
2.2M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.49
EPS
0.34
N/A
Revenue
$965,658,000.00
$30,914,000.00
Revenue This Year
N/A
$282.64
Revenue Next Year
N/A
$72.25
P/E Ratio
$10.07
N/A
Revenue Growth
N/A
209.14
52 Week Low
$2.61
$4.01
52 Week High
$8.63
$11.25

Technical Indicators

Market Signals
Indicator
BMBL
VSTM
Relative Strength Index (RSI) 35.74 35.36
Support Level $2.68 N/A
Resistance Level $3.85 $6.79
Average True Range (ATR) 0.26 0.37
MACD -0.12 -0.14
Stochastic Oscillator 0.00 14.29

Price Performance

Historical Comparison
BMBL
VSTM

About BMBL Bumble Inc.

Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: